A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Malignant melanoma; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
    • 04 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2018.
    • 23 May 2017 According to an Aeglea Biotherapeutics media release, the company has selected three single agent solid tumor expansion arms: cutaneous melanoma, uveal melanoma and small cell lung cancer. Each expansion arm will enroll up to 12 patients and are planned to initiate in the fourth quarter of 2017 or first quarter of 2018, following completion of the dose escalation phase.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top